Pfizer target raised to $40 despite trading above consensus
Alpha Vantage · Yahoo! Finance Canada · · AI-summarised by FinFlash
Argus raised its price target for Pfizer Inc. (PFE) to $40, maintaining a positive outlook on the pharmaceutical and biotech drug developer. The report highlights Pfizer's diverse product portfolio, including oncology, immunology, rare disease treatments, and vaccines. This upgrade comes as senior analyst David H. Toung continues to cover the healthcare sector.
Understand the context
Published information may change. Summaries can contain errors; check the original source. Educational information only, not investment advice.